Abstract
Background: Mitochondrial function and energy metabolism are impaired in neurodegenerative diseases. There is evidence for these functional declines both within the brain and systemically in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Due to these observations, therapeutics targeted to alter mitochondrial function and energy pathways are increasingly studied in pre-clinical and clinical settings.
Methods: The goal of this article was to review therapies with specific implications on mitochondrial energy metabolism published through May 2016 that have been tested for treatment of neurodegenerative diseases. Results: We discuss implications for mitochondrial dysfunction in neurodegenerative diseases and how this drives new therapeutic initiatives. Conclusion: Thus far, treatments have achieved varying degrees of success. Further investigation into the mechanisms driving mitochondrial dysfunction and bioenergetic failure in neurodegenerative diseases is warranted.Keywords: Mitochondria, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, Bioenergetics, Oxidative Stress, neurodegeneration.
Current Pharmaceutical Design
Title:New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders
Volume: 23 Issue: 5
Author(s): Heather M. Wilkins and Jill K. Morris*
Affiliation:
- Department of Neurology, University of Kansas Medical Center, Kansas City, KS,United States
Keywords: Mitochondria, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, Bioenergetics, Oxidative Stress, neurodegeneration.
Abstract: Background: Mitochondrial function and energy metabolism are impaired in neurodegenerative diseases. There is evidence for these functional declines both within the brain and systemically in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Due to these observations, therapeutics targeted to alter mitochondrial function and energy pathways are increasingly studied in pre-clinical and clinical settings.
Methods: The goal of this article was to review therapies with specific implications on mitochondrial energy metabolism published through May 2016 that have been tested for treatment of neurodegenerative diseases. Results: We discuss implications for mitochondrial dysfunction in neurodegenerative diseases and how this drives new therapeutic initiatives. Conclusion: Thus far, treatments have achieved varying degrees of success. Further investigation into the mechanisms driving mitochondrial dysfunction and bioenergetic failure in neurodegenerative diseases is warranted.Export Options
About this article
Cite this article as:
Wilkins M. Heather and Morris K. Jill *, New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders, Current Pharmaceutical Design 2017; 23 (5) . https://dx.doi.org/10.2174/1381612822666161230144517
DOI https://dx.doi.org/10.2174/1381612822666161230144517 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine
CNS & Neurological Disorders - Drug Targets The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Physically Cross-linked Hydrogels of β -cyclodextrin Polymer and Poly(ethylene glycol)-cholesterol as Delivery Systems for Macromolecules and Small Drug Molecules
Current Drug Delivery Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs
Current Medicinal Chemistry Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Large-Conductance Ca2+-Activated K+ Channels:Physiological Role and Pharmacology
Current Medicinal Chemistry Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets Role of Dietary Antioxidants in Neurodegenerative Diseases: Where are We Standing?
Current Pharmaceutical Design Stem Cells and Translational Medicine: From Research to Clinical Procedures
Current Tissue Engineering (Discontinued) Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Activity-dependent Synaptic Plasticity and Metaplasticity in Spinal Motor Networks
Current Pharmaceutical Design DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Evidence Linking Protein Misfolding to Quality Control in Progressive Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Biological Activity of Some Volatile Diterpenoids
Current Bioactive Compounds Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents Protein Misfolding Diseases and Therapeutic Approaches
Current Protein & Peptide Science